Among sell-side analysts on Wall Street, Morgan Stanley is one of the most well-known. The company’s large investment banking ...

We recently compiled a list of the 10 AI Stocks to Watch Amid the DeepSeek Buzz. In this article, we are going to take a look ...

Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ziclumeran ...

Exelixis (NASDAQ:EXEL) shares, with a market capitalization of $9.2 billion, received an optimistic update from Morgan Stanley (NYSE:MS), as the firm's analyst Sean Laaman upgraded the ...

Morgan Stanley (NYSE:MS) reaffirmed its Overweight rating and $430.00 price target for Tesla stock (NASDAQ:TSLA), highlighting the company's potential in the growing field of embodied artificial ...

Morgan Stanley (NYSE:MS) reaffirmed its Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT), an $11.27 billion market cap biotechnology company, with a steady price target of $200.00. The ...

We recently published an article titled Jim Cramer Discusses These 18 Stocks & President Trump’s $500 Billion AI Plan. In ...

Morgan Stanley (NYSE:MS) reiterated an Overweight rating on GDS Holdings (NASDAQ:GDS), maintaining a price target of $30.00.

Morgan Stanley (NYSE:MS) released a report on the potential industry implications of the recent launch of DeepSeek R1, an open-sourced model that could potentially match the performance of GPT o1 at ...

Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral ...

Confluent (NASDAQ:CFLT) shares fell 3% in premarket trading on Thursday after Morgan Stanley downgraded the streaming ...

Investing.com - The emergence of Chinese start-up DeepSeek's cut-price artificial intelligence model suggests the expenses related to training similar models is set to decline "substantially", ...